Tekmira Pharmaceuticals, a company specializing in RNA interference (RNAi) therapeutics, announced that Alnylam Pharmaceuticals has reported its Phase 1 clinical trial results for ALN-TTR02, an RNAi therapeutic that uses Tekmira's lipid nanoparticle delivery platform to target transthyretin (TTR) for TTR-mediated amyloidosis (ATTR) treatment.
ALN-TTR02 is produced by Tekmira Pharmaceuticals. Alnylam Pharmaceuticals presented the latest results at Boston University School of Medicine. The results demonstrated that ALN-TTR02 administration considerably lowered the serum levels of TTR proteins by about 94%. For a single dose, knockdown of the disease-causing TTR protein in ATTR was specific, quick, long-lasting, and based on the dosage.
Alnylam Pharmaceuticals recently announced the start of a Phase 2 clinical trial of ALN-TTR02 in patients having ATTR, with an objective to initiate a pivotal study in the fiscal year 2013. The commencement of the Phase 2 clinical trial of ALN-TTR02 generated a landmark payment to Tekmira Pharmaceuticals.
Tekmira Pharmaceuticals’ President and Chief Executive Officer, Dr. Mark J. Murray stated that these positive results on the Phase 1 clinical study of ALN-TTR02 further corroborate Tekmira Pharmaceuticals’ proven lipid nanoparticle delivery technology as the gold standard to make possible RNAi therapeutics that are in the company’s pipeline and those of its partners for a myriad of clinical indications.